Q Therapeutics, Inc. 4
4 · Q Therapeutics, Inc. · Filed Mar 13, 2014
Insider Transaction Report
Form 4
Q Therapeutics, Inc.[NONE]
BORST STEVEN JOHN
CFO & VP of Corp. Development
Transactions
- Award
Option to Purchase Common Stock
2014-03-11$0.70/sh+102,002$71,401→ 1,886,674 totalExercise: $0.70From: 2014-03-11Exp: 2024-03-10→ Common Stock (102,002 underlying) - Award
Option to Purchase Common Stock
2014-03-11$0.70/sh+250,000$175,000→ 1,886,674 totalExercise: $0.70From: 2014-03-11Exp: 2024-03-10→ Common Stock (250,000 underlying) - Award
Option to Purchase Common Stock
2014-03-11$0.70/sh+200,000$140,000→ 1,886,674 totalExercise: $0.70From: 2014-03-11Exp: 2024-03-10→ Common Stock (200,000 underlying) - Award
Option to Purchase Common Stock
2014-03-11$0.70/sh+250,000$175,000→ 1,886,674 totalExercise: $0.70From: 2014-04-11Exp: 2024-03-10→ Common Stock (250,000 underlying)
Footnotes (4)
- [F1]Grant relates to the 2013 annual employee grant. Upon grant, 58,333 options immediately vest and are exercisable, with 141,667 options vesting equally over the remaining 34 months.
- [F2]Grant relates to the 2014 annual employee grant. Upon grant, 10,417 options immediately vest and are exercisable, with 239,583 options vesting equally over the remaining 46 months.
- [F3]Grant relates to compensation resulting from the executive's salary deferral that occurred in 2013. All options fully vested upon grant.
- [F4]Options vest monthly in equal increment over twelve months.